{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:13:28Z","timestamp":1793916808446,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n This study was designed to evaluate the protective effects of AMPK\u03b1 and SIRT1 on insulin resistance in PCOS rats, and to illuminate the underlying mechanisms.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n An in vitro PCOS model was established by DHEA (6\u2009mg\/(100\u2009g\u2022d)), and the rats were randomly divided into the metformin group (MF group, n<\/jats:italic>\u00a0=\u200911), the exenatide group (EX group, n<\/jats:italic>\u2009=\u200911), the PCOS group (n<\/jats:italic>\u00a0=\u200910), and the normal control group (NC group, n<\/jats:italic>\u2009=\u200910). The MF group was administered MF 300\u2009mg\/(kg\u2022d) daily. The EX group was subcutaneously injected EX 10\u03bcg\/(kg\u2022d) daily. After 4\u2009weeks of continuous administration, fasting blood glucose and serum androgen, luteinizing hormone and other biochemical indicators were measured. Western and Real-time PCR were used to determine the expression of AMPK\u03b1 and SIRT1 in the ovaries of each group.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After 4\u2009weeks of drug intervention, compared with untreated PCOS group, EX group and MF group had visibly decreased body weight (222.64\u2009\u00b1\u200916.57, 218.63\u2009\u00b1\u200913.18 vs 238.30\u2009\u00b1\u200912.26\u2009g, P<\/jats:italic>\u00a0=\u20090.026), fasting blood glucose (7.71\u2009\u00b1\u20090.72, 8.17\u2009\u00b1\u20090.54 vs 8.68\u2009\u00b1\u20090.47\u2009mmol\/L, P<\/jats:italic>\u00a0<\u20090.01), HOMA-IR (8.26\u2009\u00b1\u20092.50, 7.44\u2009\u00b1\u20091.23 vs 12.66\u2009\u00b1\u20091.44, P<\/jats:italic>\u00a0<\u20090.01) and serum androgen (0.09\u2009\u00b1\u20090.03, 0.09\u2009\u00b1\u20090.03 vs 0.53\u2009\u00b1\u20090.41\u2009ng\/ml, P<\/jats:italic>\u00a0<\u20090.01) and the expressions of AMPK\u03b1 and SIRT11 were increased progressively (P<\/jats:italic>\u00a0<\u20090.05).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Both metformin and exenatide can improve the reproductive and endocrine functions of rats with PCOS via the AMPK\u03b1-SIRT1 pathway, which may be the molecular mechanism for IR in PCOS and could possibly serve as a therapeutic target.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13048-019-0555-8","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T10:04:21Z","timestamp":1568628261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Effects of metformin and Exenatide on insulin resistance and AMPK\u03b1-SIRT1 molecular pathway in PCOS rats"],"prefix":"10.1186","volume":"12","author":[{"given":"Xin","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"555_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/humupd\/dmp008","volume":"15","author":"L Moran","year":"2009","unstructured":"Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update. 2009;15:477\u201388. \n https:\/\/doi.org\/10.1093\/humupd\/dmp008\n \n .","journal-title":"Hum Reprod Update"},{"key":"555_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2217\/whe.09.39","volume":"5","author":"AL Hirschberg","year":"2009","unstructured":"Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Women Health. 2009;5:529\u201342. \n https:\/\/doi.org\/10.2217\/whe.09.39\n \n .","journal-title":"Women Health"},{"key":"555_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.fertnstert.2018.08.021","volume":"110","author":"LG Cooney","year":"2018","unstructured":"Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110:794\u2013809. \n https:\/\/doi.org\/10.1016\/j.fertnstert.2018.08.021\n \n .","journal-title":"Fertil Steril"},{"key":"555_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-09-0733","volume":"162","author":"E Diamanti-Kandarakis","year":"2010","unstructured":"Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162:193\u2013212. \n https:\/\/doi.org\/10.1530\/EJE-09-0733\n \n .","journal-title":"Eur J Endocrinol"},{"key":"555_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647\u201354. \n https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7\n \n .","journal-title":"Metabolism"},{"key":"555_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2337\/db07-0381.Additional","volume":"57","author":"YD Kim","year":"2008","unstructured":"Kim YD, Park K, Lee Y, Park Y, Kim D, Nedumaran B, et al. AMP-activated protein kinase \u2013 dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57:306\u201314. \n https:\/\/doi.org\/10.2337\/db07-0381.Additional\n \n .","journal-title":"Diabetes"},{"key":"555_CR7","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1210\/jc.2004-2283","volume":"90","author":"RH Lyndal","year":"2005","unstructured":"Lyndal RH, Naveed S, Jane EN, Richard F. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90:4593\u20138. \n https:\/\/doi.org\/10.1210\/jc.2004-2283\n \n .","journal-title":"J Clin Endocrinol Metab"},{"key":"555_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/304368a0","volume":"304","author":"GI Bell","year":"1983","unstructured":"Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304:368\u201371. \n https:\/\/doi.org\/10.1038\/304368a0\n \n .","journal-title":"Nature"},{"key":"555_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u201342. \n https:\/\/doi.org\/10.1038\/nrendo.2012.140\n \n .","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"555_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87(6):767\u201374. \n https:\/\/doi.org\/10.1111\/cen.13454\n \n .","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"555_CR11","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7):2670\u20138. \n https:\/\/doi.org\/10.1210\/jc.2008-0115\n \n .","journal-title":"J Clin Endocrinol Metab"},{"key":"555_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.bbrc.2017.09.154","volume":"494","author":"X Tao","year":"2017","unstructured":"Tao X, Chen L, Cai L, Ge S, Deng X. Regulatory effects of the AMPK\u03b1-SIRT1 molecular pathway on insulin resistance in PCOS mice: an in vitro and in vivo study. Biochem Biophys Res Commun. 2017;494:615\u201320. \n https:\/\/doi.org\/10.1016\/j.bbrc.2017.09.154\n \n .","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"555_CR13","first-page":"8276","volume":"8","author":"X Tao","year":"2015","unstructured":"Tao X, Zhang X, Ge SQ, Zhang EH, Zhang B. Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. Int J Clin Exp Pathol. 2015;8(7):8276\u201383.","journal-title":"Int J Clin Exp Pathol"},{"key":"555_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/oxfordjournals.humrep.a136365","volume":"2","author":"A Gougeon","year":"1986","unstructured":"Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod. 1986;2:81\u20137. \n https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a136365\n \n .","journal-title":"Hum Reprod"},{"key":"555_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/humupd\/dms029.","volume":"18","author":"SM Veltman-Verhulst","year":"2012","unstructured":"Veltman-Verhulst SM, Boivin J, et al. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update. 2012;18:638\u201351. \n https:\/\/doi.org\/10.1093\/humupd\/dms029.","journal-title":"Hum Reprod Update"},{"key":"555_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0038-1668085","volume":"36","author":"ACH Neven","year":"2018","unstructured":"Neven ACH, Laven J, Teede HJ, Boyle JA. A summary on polycystic ovary syndrome: diagnostic criteria, prevalence, clinical manifestations, and management according to the latest international guidelines. Semin Reprod Med. 2018;36:5\u201312. \n https:\/\/doi.org\/10.1055\/s-0038-1668085\n \n .","journal-title":"Semin Reprod Med"},{"key":"555_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.molmed.2006.05.006","volume":"12","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12:324\u201332.","journal-title":"Trends Mol Med"},{"key":"555_CR18","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"S Cassar","year":"2016","unstructured":"Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016;31:2619\u201331. \n https:\/\/doi.org\/10.1093\/humrep\/dew243\n \n .","journal-title":"Hum Reprod"},{"key":"555_CR19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1017\/CBO9781107415324.004","volume":"53","author":"DR Tobergte","year":"2013","unstructured":"Tobergte DR, Curtis S. Metformin inhibits intra-cellular lipid accumulation in the murine preadipocyte cell line, 3T3-L1. J Chem Inf Model. 2013;53:1689\u201399. \n https:\/\/doi.org\/10.1017\/CBO9781107415324.004\n \n .","journal-title":"J Chem Inf Model"},{"key":"555_CR20","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1126\/science.1120781","volume":"310","author":"RJ Shaw","year":"2005","unstructured":"Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DePinho RA, et al. Medicine: the kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (80- ). 2005;310:1642\u20136. \n https:\/\/doi.org\/10.1126\/science.1120781\n \n .","journal-title":"Science (80- )"},{"key":"555_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bph.12496","volume":"171","author":"G Arunachalam","year":"2014","unstructured":"Arunachalam G, Samuel SM, Marei I, Ding H, Triggle CR. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol. 2014;171:523\u201335. \n https:\/\/doi.org\/10.1111\/bph.12496\n \n .","journal-title":"Br J Pharmacol"},{"key":"555_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nature07813","volume":"458","author":"C Canto\u00b4","year":"2009","unstructured":"Canto\u00b4 C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 2009;458:1056\u201360. \n https:\/\/doi.org\/10.1038\/nature07813\n \n .","journal-title":"Nature"},{"key":"555_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbadis.2017.10.014","volume":"1864","author":"D Rogacka","year":"2018","unstructured":"Rogacka D, Audzeyenka I, Rych\u0142owski M, Rachubik P, Szrejder M, Angielski S, et al. Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. Biochim Biophys Acta - Mol Basis Dis. 2018;1864:115\u201325. \n https:\/\/doi.org\/10.1016\/j.bbadis.2017.10.014\n \n .","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"555_CR24","doi-asserted-by":"publisher","first-page":"C4","DOI":"10.1152\/ajpcell.00296.2011","volume":"303","author":"LE Nelson","year":"2012","unstructured":"Nelson LE, Valentine RJ, Cacicedo JM, Gauthier M-S, Ido Y, Ruderman NB. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Physiol. 2012;303:C4\u201313. \n https:\/\/doi.org\/10.1152\/ajpcell.00296.2011\n \n .","journal-title":"Am J Physiol Physiol"},{"key":"555_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2016.04.024","volume":"232","author":"N Shrestha","year":"2016","unstructured":"Shrestha N, Ara\u00fajo F, Shahbazi MA, M\u00e4kil\u00e4 E, Gomes MJ, Airavaara M, et al. Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal model. J Control Release. 2016;232:113\u20139. \n https:\/\/doi.org\/10.1016\/j.jconrel.2016.04.024\n \n .","journal-title":"J Control Release"},{"key":"555_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-0985-7","volume":"14","author":"F Andreozzi","year":"2016","unstructured":"Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, et al. The GLP-1 receptor agonists exenatide and liraglutide activate glucose transport by an AMPK-dependent mechanism. J Transl Med. 2016;14:1\u201313. \n https:\/\/doi.org\/10.1186\/s12967-016-0985-7\n \n .","journal-title":"J Transl Med"},{"key":"555_CR27","first-page":"8641","volume":"89","author":"B Thorens","year":"1992","unstructured":"Thorens B. Expression cloning of the pancreatic J8 cell receptor for the gluco-incretin hormone glucagon-like peptide 1 (insulin secretion\/non-insulin-dependent diabetes mellitus\/entero-insular axis\/G proteins\/cAMP). Cell Biol. 1992;89:8641\u20135.","journal-title":"Cell Biol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0555-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0555-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T23:12:26Z","timestamp":1600125146000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0555-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["555"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0555-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving rats were carried out in accordance with the strict standards of the National Institutes of Health guide for the care and use of laboratory animals, and the program was approved by the Institutional Animal Care and Use Commitee of Sun Yat-sen University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}